Application of the ACOSOG Z0011 criteria to Chinese patients with breast cancer: a prospective study
Abstract Background Although the ACOSOG Z0011 study showed that axillary lymph node dissection (ALND) could be avoided in a specific population of sentinel lymph node-positive patients, it is not widely accepted by Chinese surgeons. We conducted a prospective single-arm study to confirm whether or n...
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-04-01
|
Series: | World Journal of Surgical Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12957-021-02242-1 |
id |
doaj-9ff3e57d86ab43a69f5114c507734c37 |
---|---|
record_format |
Article |
spelling |
doaj-9ff3e57d86ab43a69f5114c507734c372021-04-25T11:25:33ZengBMCWorld Journal of Surgical Oncology1477-78192021-04-011911910.1186/s12957-021-02242-1Application of the ACOSOG Z0011 criteria to Chinese patients with breast cancer: a prospective studyYuan Peng0Miao Liu1Xianan Li2Fuzhong Tong3Yingming Cao4Peng Liu5Bo Zhou6Hongjun Liu7Lin Cheng8Jiajia Guo9Fei Xie10Houpu Yang11Siyuan Wang12Chaobin Wang13Yalin Chen14Shu Wang15Breast Center, Peking University People’s HospitalBreast Center, Peking University People’s HospitalRadiotherapy Department, Peking University People’s HospitalBreast Center, Peking University People’s HospitalBreast Center, Peking University People’s HospitalBreast Center, Peking University People’s HospitalBreast Center, Peking University People’s HospitalBreast Center, Peking University People’s HospitalBreast Center, Peking University People’s HospitalBreast Center, Peking University People’s HospitalBreast Center, Peking University People’s HospitalBreast Center, Peking University People’s HospitalBreast Center, Peking University People’s HospitalBreast Center, Peking University People’s HospitalRadiotherapy Department, Peking University People’s HospitalBreast Center, Peking University People’s HospitalAbstract Background Although the ACOSOG Z0011 study showed that axillary lymph node dissection (ALND) could be avoided in a specific population of sentinel lymph node-positive patients, it is not widely accepted by Chinese surgeons. We conducted a prospective single-arm study to confirm whether or not the results of Z0011 are applicable to Chinese patients. Methods Patients conforming to the Z0011 criteria were prospectively enrolled at the Peking University People’s Hospital Breast Center from November 2014 to June 2019. The clinicopathological features of the study group were compared with those of the Z0011 study group. Lymphedema after surgery, the incidence of local-regional recurrence, and survival were analyzed. Results One hundred forty-two patients who met the Z0011 eligibility criteria were enrolled in this study; 115 underwent sentinel lymph node biopsy (SLNB) alone. Compared with the Z0011 trial, younger patients were included (median age, 52 [26–82] years vs 54 [25–90] years; P = 0.03). For clinical T stage, tumor histology, hormone status, lymphovascular invasion, and the number of positive sentinel lymph nodes (SLNs), no statistically significant differences were observed. More patients received adjuvant chemotherapy and endocrine therapy in this study (90.85% vs 58.0% and 80.99% vs 46.6% respectively, P <0.001). A similar percentage of patients received radiotherapy, but more nodal radiotherapy procedures were carried out in our study (54.5% vs 16.9%). After a median follow-up of 29 months, only 1 patient (0.9%) had ipsilateral breast tumor recurrence, and no regional recurrence occurred. Conclusion Our study showed that it is achievable to avoid ALND in patients eligible for Z0011 in China. Trial registration ClinicalTrials.gov. Registration number NCT03606616 . Retrospectively registered on 31 July 2018.https://doi.org/10.1186/s12957-021-02242-1Breast cancerSentinel lymph nodeACOSOG Z0011Chinese |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yuan Peng Miao Liu Xianan Li Fuzhong Tong Yingming Cao Peng Liu Bo Zhou Hongjun Liu Lin Cheng Jiajia Guo Fei Xie Houpu Yang Siyuan Wang Chaobin Wang Yalin Chen Shu Wang |
spellingShingle |
Yuan Peng Miao Liu Xianan Li Fuzhong Tong Yingming Cao Peng Liu Bo Zhou Hongjun Liu Lin Cheng Jiajia Guo Fei Xie Houpu Yang Siyuan Wang Chaobin Wang Yalin Chen Shu Wang Application of the ACOSOG Z0011 criteria to Chinese patients with breast cancer: a prospective study World Journal of Surgical Oncology Breast cancer Sentinel lymph node ACOSOG Z0011 Chinese |
author_facet |
Yuan Peng Miao Liu Xianan Li Fuzhong Tong Yingming Cao Peng Liu Bo Zhou Hongjun Liu Lin Cheng Jiajia Guo Fei Xie Houpu Yang Siyuan Wang Chaobin Wang Yalin Chen Shu Wang |
author_sort |
Yuan Peng |
title |
Application of the ACOSOG Z0011 criteria to Chinese patients with breast cancer: a prospective study |
title_short |
Application of the ACOSOG Z0011 criteria to Chinese patients with breast cancer: a prospective study |
title_full |
Application of the ACOSOG Z0011 criteria to Chinese patients with breast cancer: a prospective study |
title_fullStr |
Application of the ACOSOG Z0011 criteria to Chinese patients with breast cancer: a prospective study |
title_full_unstemmed |
Application of the ACOSOG Z0011 criteria to Chinese patients with breast cancer: a prospective study |
title_sort |
application of the acosog z0011 criteria to chinese patients with breast cancer: a prospective study |
publisher |
BMC |
series |
World Journal of Surgical Oncology |
issn |
1477-7819 |
publishDate |
2021-04-01 |
description |
Abstract Background Although the ACOSOG Z0011 study showed that axillary lymph node dissection (ALND) could be avoided in a specific population of sentinel lymph node-positive patients, it is not widely accepted by Chinese surgeons. We conducted a prospective single-arm study to confirm whether or not the results of Z0011 are applicable to Chinese patients. Methods Patients conforming to the Z0011 criteria were prospectively enrolled at the Peking University People’s Hospital Breast Center from November 2014 to June 2019. The clinicopathological features of the study group were compared with those of the Z0011 study group. Lymphedema after surgery, the incidence of local-regional recurrence, and survival were analyzed. Results One hundred forty-two patients who met the Z0011 eligibility criteria were enrolled in this study; 115 underwent sentinel lymph node biopsy (SLNB) alone. Compared with the Z0011 trial, younger patients were included (median age, 52 [26–82] years vs 54 [25–90] years; P = 0.03). For clinical T stage, tumor histology, hormone status, lymphovascular invasion, and the number of positive sentinel lymph nodes (SLNs), no statistically significant differences were observed. More patients received adjuvant chemotherapy and endocrine therapy in this study (90.85% vs 58.0% and 80.99% vs 46.6% respectively, P <0.001). A similar percentage of patients received radiotherapy, but more nodal radiotherapy procedures were carried out in our study (54.5% vs 16.9%). After a median follow-up of 29 months, only 1 patient (0.9%) had ipsilateral breast tumor recurrence, and no regional recurrence occurred. Conclusion Our study showed that it is achievable to avoid ALND in patients eligible for Z0011 in China. Trial registration ClinicalTrials.gov. Registration number NCT03606616 . Retrospectively registered on 31 July 2018. |
topic |
Breast cancer Sentinel lymph node ACOSOG Z0011 Chinese |
url |
https://doi.org/10.1186/s12957-021-02242-1 |
work_keys_str_mv |
AT yuanpeng applicationoftheacosogz0011criteriatochinesepatientswithbreastcanceraprospectivestudy AT miaoliu applicationoftheacosogz0011criteriatochinesepatientswithbreastcanceraprospectivestudy AT xiananli applicationoftheacosogz0011criteriatochinesepatientswithbreastcanceraprospectivestudy AT fuzhongtong applicationoftheacosogz0011criteriatochinesepatientswithbreastcanceraprospectivestudy AT yingmingcao applicationoftheacosogz0011criteriatochinesepatientswithbreastcanceraprospectivestudy AT pengliu applicationoftheacosogz0011criteriatochinesepatientswithbreastcanceraprospectivestudy AT bozhou applicationoftheacosogz0011criteriatochinesepatientswithbreastcanceraprospectivestudy AT hongjunliu applicationoftheacosogz0011criteriatochinesepatientswithbreastcanceraprospectivestudy AT lincheng applicationoftheacosogz0011criteriatochinesepatientswithbreastcanceraprospectivestudy AT jiajiaguo applicationoftheacosogz0011criteriatochinesepatientswithbreastcanceraprospectivestudy AT feixie applicationoftheacosogz0011criteriatochinesepatientswithbreastcanceraprospectivestudy AT houpuyang applicationoftheacosogz0011criteriatochinesepatientswithbreastcanceraprospectivestudy AT siyuanwang applicationoftheacosogz0011criteriatochinesepatientswithbreastcanceraprospectivestudy AT chaobinwang applicationoftheacosogz0011criteriatochinesepatientswithbreastcanceraprospectivestudy AT yalinchen applicationoftheacosogz0011criteriatochinesepatientswithbreastcanceraprospectivestudy AT shuwang applicationoftheacosogz0011criteriatochinesepatientswithbreastcanceraprospectivestudy |
_version_ |
1721509767257522176 |